



BioLight Life Sciences Ltd.
(the “Company”)

October 9 2023

Re: **DiagnosTear Ltd. (Subsidiary) –**
recruitment of first participant in a clinical trial in Israel

BioLight hereby announces that its subsidiary, Diagnostear Ltd. ("Diagnostear") has informed it that it has recruited the first participant in a clinical trial in humans in Israel aimed at collecting tears from red eye¹ patients for the purpose of developing a differential diagnosis test between conjunctivitis caused by adenovirus , allergic conjunctivitis and keratitis caused by the herpes virus.

To the best of the BioLight's knowledge, as informed by Diagnostear, the clinical trial, which is conducted in collaboration with Leumit Health Care Services, is expected to include approximately 200 participants suffering from symptoms of red eye.

According to Diagnostear, in accordance with and subject to the rate of participant recruitment, the clinical trial is expected to end in the second quarter of 2024.

***Forward Looking Statement** The information and details contained in this report regarding the clinical trial as well as predictions, deadlines, assessments and/or plans of the company and/or Diagnostear in connection with the aforementioned, including in connection with the rate of recruitment of participants and the end date of the clinical trial, the achievement of the goals of the trial (if any) as well as further examination and development, are "Forward-looking information" as defined in the Israeli Securities Law, 1968-5778 which involves high*

¹ Red eye is a general description of superficial redness in the eyeball which can be caused by several factors. Among the common causes are viral, bacterial or allergic conjunctivitis, herpes virus infection, dry eye or subconjunctival hemorrhage.

uncertainty, and is based, among other things, on third parties and on many variables over which the Company and/or Diagnostear do not necessarily have control, and therefore it is possible that the aforementioned information and estimates, in practice will not be realized and/or will not be fully realized and/or will be realized in a materially different way than was initially estimated or observed, including as a result of any of the risk factors as detailed in Section 4.27 in Chapter A of the Company's annual report, which may have a significant effect, together and separately, on the Company's estimates as mentioned above.

About DiagnosTear

DiagnosTear develops the TeaRx™ Technology designed for the identification, diagnosis, adjustment of treatment, and follow-up of diseases in the front of the eye by examining the composition of the tear fluid

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.

Free translation: non-binding.

This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli SEC – created for convenience purposes only. In case of contradiction, the Hebrew version will take precedence.